Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
CA2943334 A1 2015-09-24 [CA2943334] / 2015-09-24
申请号/申请日
2015CA-2943334 / 2015-03-19
发明人
CHANG CHIH-LONG;WU CHAO-CHIH;
申请人
MACKAY MEDICAL FOUND THE PRESBYTERIAN CHURCH TAIWAN MACKAY MEMORIAL HOSPITAL;
主分类号
IPC分类号
A01N-043/04A61K-039/00A61K-045/00
摘要
(CA2943334) Disclosed herein are an immunogenic glycopeptide for inducing immune response to treat cancer.  Other aspects of the present disclosure are pharmaceutical composition comprising the immunogenic glycopeptide; and method for preventing and/or treating a cancer.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2014US-61955216 2014-03-19 2015WO-US21421 2015-03-19
主权利要求
(CA2943334)  Claims What is claimed is: 1. An immunogenic glycopeptide, wherein the immunogenic glycopeptide has the structure of: wherein the PADRE is a pan-DR epitope and has at least 10 consecutive amino acid residues that is at least 80% identical to the amino acid sequence of AKXVAAWTLKAAA (SEQ ID No. 1), where X is a cyclohexylalanine residue;  and wherein P is Globo H, GD2, GM2, SSEA 4, Lewis, LewisY or STn. 2. The immunogenic glycopeptide of claim 1, wherein the amino acid sequence of the PADRE is identical to the amino acid sequence of SEQ ID No. 1. 3. The immunogenic glycopeptide of claim 1, wherein P is Globo H, GM2, SSEA 4 or Lewis Y. 4. The immunogenic glycopeptide of claim 1, wherein the last residue (K) is omitted. 5. The immunogenic glycopeptide of claim 1, wherein the the first residue (A) or the first two residues (A and K) are omitted. 6. A pharmaceutical composition, comprising a therapeutically effective amount of one or more immunogenic glycopeptide of Claim 1 and a pharmaceutically acceptable carrier or adjuvant. 7. The pharmaceutical composition of Claim 6, wherein the adjuvant is QS21 or aluminum hydroxide. 8. The pharmaceutical composition of Claim 6, wherein the composition is a vaccine. 9. The pharmaceutical composition of Claim 8, wherein the vaccine is a polyvalent vaccine comprising one or more Globo H-, GM2-, Lewis Y, or SSEA4-PADRE glycopeptide as defined in Claim 1. 10. The pharmaceutical composition of Claim 9, wherein the polyvalent vaccine comprises Globo H-, GM2- and Lewis Y-PADRE glycopeptides or SSEA4-, GM2- and Lewis Y-PADRE glycopeptides. 11. A method for preventing and/or treating a cancer, comprises administering an effective amount of one or more immunogenic glycopeptide of Claim 1 to a subject. 12. A method for preventing and/or treating a cancer, comprises administering an effective amount of the pharmaceutical composition of Claim 6 to a subject. 13. A method for preventing and/or treating a cancer, comprises administering an effective amount of the pharmaceutical composition of Claim 9 to a subject. 14. A method for preventing and/or treating a cancer, comprises administering an effective amount of the pharmaceutical composition of Claim 10 to a subject. 15. The method of any of Claims 11 to 14, wherein the cancer is a tumorassociated carbohydrate-expressing cancer. 16. The method of Claim 15, wherein the cancer is breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer or lung cancer.
法律状态
(CA2943334) LEGAL DETAILS FOR CA2943334  Actual or expected expiration date=2035-03-19    Legal state=ALIVE    Status=PENDING     Event publication date=2015-03-19  Event code=CA/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=CA CA2943334  Application date=2015-03-19  Standardized application number=2015CA-2943334     Event publication date=2015-09-24  Event code=CA/A1  Event type=Examination events  Application laid open  Publication country=CA  Publication number=CA2943334  Publication stage Code=A1  Publication date=2015-09-24  Standardized publication number=CA2943334
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部